Gilead Sciences Inc (GILD)

Add to Watchlists
Create an Alert
66.87 -0.34  -0.51% NASDAQ Jul 19, 10:27 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
10/25/2019 16:30 EDT Misc Gilead Sciences Inc Third Quarter Earnings Conference Call in 2019
10/25/2019 Earnings Gilead Sciences Inc Third Quarter Earnings in 2019 Release
07/30/2019 16:30 EDT Misc Gilead Sciences Inc Second Quarter Earnings Conference Call in 2019
07/30/2019 Earnings Gilead Sciences Inc Second Quarter Earnings in 2019 Release
06/13/2019 Dividends Amount: 0.63, Declared Date: May 02 2019, Pay Date: Jun 27 2019
05/08/2019 10:00 PDT Misc Gilead Sciences Inc Annual General Meeting in 2018
05/02/2019 16:30 EDT Misc Gilead Sciences Inc First Quarter Earnings Conference Call in 2019
05/02/2019 Earnings Gilead Sciences Inc First Quarter Earnings in 2019 Release
03/14/2019 Dividends Amount: 0.63, Declared Date: Feb 04 2019, Pay Date: Mar 28 2019
02/26/2019 Misc Gilead Sciences Inc Annual Report in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.gilead.com
  • Investor Relations URL: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-irhome
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Equity Style: Large Cap/Value
  • Next Earnings Release: Jul. 30, 2019
  • Last Earnings Release: May. 02, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: Jun. 13, 2019
  • Description: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition boosted Gilead's exposure to cell therapy in oncology.

Top Fund Holders

Symbol Name Weighting
IBB iShares Nasdaq Biotechnology ETF 8.11%
FBIOX Fidelity® Select Biotechnology 6.71%
FBT First Trust NYSE Arca Biotech ETF 3.51%
XLV Health Care Select Sector SPDR® ETF 2.46%
VHT Vanguard Health Care ETF 2.09%
PRBLX Parnassus Core Equity Investor 2.04%
RICHX American Funds Invmt Co of Amer R5E 1.40%
RAEFX American Funds AMCAP R5E 1.21%
RMEBX American Funds American Mutual R2E 1.18%
QQQ Invesco QQQ Trust 1.00%
RIRHX American Funds Capital Income Bldr R5E 0.82%
IVE iShares S&P 500 Value ETF 0.74%

Comparables

Edit

Excel Add-In Codes

  • Name: =YCI("GILD","name")
  • Description: =YCI("GILD","description")
  • Sector: =YCI("GILD","sector")
  • Industry: =YCI("GILD","industry")
  • Est. Current Fiscal Year End: =YCI("GILD","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.